Cancer
(CANCER-AM CANCER SOC) 《癌症》

网友评分点击次数：201

2011年影响因子
4.771

全球精选文摘

全球精选全文

2012-10-17•长期癌症存活者更容易请病假
2012-10-17•新研究显示为什么晚期癌症在靶向治疗后会复发
2012-10-17•药物帮助减缓晚期前列腺癌进展
2012-10-17•儿童癌症进展：全基因组测序已帮助确定癌症亚型和潜在治疗靶点
2012-10-17•60岁和＜60岁男性前列腺癌质子质量后勃起功能，尿失禁和其他生活质量结局
2012-08-06•产业界对研究的支持与日俱增

中国作者重要发表

Published 2012年9月,Volume 118,Issue 17

最新一期

CancerScope
1. You have free access to this content
  US representatives honored for their support of cancer research : The lawmakers have advocated for NIH funding, breakthrough therapies, and drug shortage solutions (pages 4095–4096)
  Carrie Printz
  
  Article first published online: 20 AUG 2012 | DOI: 10.1002/cncr.27777
  - Abstract
  - Full Article (HTML)
  - PDF(1986K)
  - Request Permissions
2. You have free access to this content
  Genetic test predicts whether eye cancer will spread (page 4096)
  Carrie Printz
  
  Article first published online: 20 AUG 2012 | DOI: 10.1002/cncr.27778
  - Abstract
  - Full Article (HTML)
  - PDF(1986K)
  - References
  - Request Permissions
3. You have free access to this content
  Studies for colorectal cancer screening not properly designed (page 4097)
  Carrie Printz
  
  Article first published online: 20 AUG 2012 | DOI: 10.1002/cncr.27779
  - Abstract
  - Full Article (HTML)
  - PDF(1986K)
  - References
  - Request Permissions
4. You have free access to this content
  High-throughput sequencing detects signs of cancer recurrence (page 4097)
  Carrie Printz
  
  Article first published online: 20 AUG 2012 | DOI: 10.1002/cncr.27780
  - Abstract
  - Full Article (HTML)
  - PDF(1986K)
  - References
  - Request Permissions
Original Articles
1. Disease Site
  
  Breast Disease
  An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer (pages 4098–4104)
  Phuong Khanh Morrow, Rashmi K. Murthy, Joe D. Ensor, Gilad S. Gordon, Kim A. Margolin, Anthony D. Elias, Walter J. Urba, David E. Weng, Hope S. Rugo and Gabriel N. Hortobagyi
  
  Article first published online: 26 JAN 2012 | DOI: 10.1002/cncr.26730
  
  This phase 2 study evaluates the objective response rate of RPI.4610 (Angiozyme), an antiangiogenic ribozyme that targets vascular endothelial growth factor receptor 1 mRNA. Although RPI.4610 demonstrates a well-tolerated safety profile, its lack of clinical efficacy precludes this drug from further development.
  - Abstract
  - Full Article (HTML)
  - PDF(174K)
  - References
  - Request Permissions
2. Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions (pages 4105–4116)
  Ji Ma, Yan Xue, Wei Cui, Yan Li, Qingli Zhao, Wenmin Ye, Jin Zheng, Yuanxiong Cheng, Yuguang Ma, Sen Li, Tenglong Han, Lu Miao, Libo Yao, Jian Zhang and Wenchao Liu
  
  Article first published online: 3 JAN 2012 | DOI: 10.1002/cncr.27393
  
  The current data suggest that activated ras homolog gene family, member A (RhoA) promotes vascular endothelial growth factor (VEGF) expression and hypoxia-induced angiogenesis through the up-regulation of the p53 binding protein homolog murine double minute 2 (MDM2) to decrease p53 stability. Data from 129 breast cancer clinical specimens with wild-type p53 reveal that high RhoA expression is correlated with high MDM2 expression, low wild-type p53 expression, and high VEGF expression.
  - Abstract
  - Full Article (HTML)
  - PDF(815K)
  - References
  - Request Permissions
3. Comparative analysis of clinicopathologic features, treatment, and survival of Asian women with a breast cancer diagnosis residing in the United States (pages 4117–4125)
  Min Yi, Peijun Liu, Xu Li, Elizabeth A. Mittendorf, Jianjun He, Yu Ren, Khazi Nayeemuddin and Kelly K. Hunt
  
  Article first published online: 3 JAN 2012 | DOI: 10.1002/cncr.27399
  
  Population-based data demonstrate breast cancer disparities in Asian patients residing in the United States as evidenced by heterogeneity in tumor characteristics and outcomes.
  - Abstract
  - Full Article (HTML)
  - PDF(194K)
  - References
  - Request Permissions
4. Outcome after ipsilateral breast tumor recurrence in patients who receive accelerated partial breast irradiation (pages 4126–4131)
  Chirag Shah, Frank Vicini, Martin Keisch, Henry Kuerer, Peter Beitsch, Bruce Haffty and Maureen Lyden
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.27400
  
  In the largest review of outcomes after ipsilateral breast tumor recurrence in patients who receive accelerated partial breast irradiation, excellent outcomes are noted with short-term follow-up. In the limited number of patients who underwent repeat breast conservation after developing a recurrence, outcomes comparable to those after traditional salvage procedures are noted.
  - Abstract
  - Full Article (HTML)
  - PDF(112K)
  - References
  - Request Permissions
5. Discipline
  
  Gastrointestinal Disease
  A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer (pages 4132–4138)
  Robert A. Wolff, Martin Fuchs, Maria Di Bartolomeo, Anwar M. Hossain, Clemens Stoffregen, Steven Nicol and Volker Heinemann
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.26692
  
  Enzastaurin combined with bevacizumab-based therapy is tolerable, but does not improve progression-free survival over bevacizumab-based therapy alone.
  - Abstract
  - Full Article (HTML)
  - PDF(159K)
  - References
  - Request Permissions
6. Disease Site
  
  Genitourinary Disease
  Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy : Results of Cancer and Leukemia Group B (CALGB) 9782 (pages 4139–4147)
  J. Paul Monk, Susan Halabi, Joel Picus, Arif Hussain, George Philips, Ellen Kaplan, Tim Ahles, Lin Gu, Nicholas Vogelzang, William K. Kelly and Eric J. Small, for the Cancer and Leukemia Group B
  
  Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26732
  
  Prostate-specific antigen failure after curative intent treatment of prostate cancer is a common scenario, and the optimal management for this disease state is unknown. The combination of finasteride and flutamide is associated with durable disease control and may prove to be an option for these men.
  - Abstract
  - Full Article (HTML)
  - PDF(296K)
  - References
  - Request Permissions
7. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy : A pilot study (pages 4148–4155)
  Hashim Uddin Ahmed, Paul Cathcart, Neil McCartan, Alex Kirkham, Clare Allen, Alex Freeman and Mark Emberton
  
  Article first published online: 3 JAN 2012 | DOI: 10.1002/cncr.27394
  
  Focal salvage therapy has been proposed as an alternative that may provide treatment for localized radiorecurrent disease while reducing the impact on functional status. This study demonstrates that focal salvage therapy using high-intensity focused ultrasound for radiorecurrent prostate cancer is feasible and appears to exhibit a favorable balance of harms and benefits.
  - Abstract
  - Full Article (HTML)
  - PDF(233K)
  - References
  - Request Permissions
8. Hematologic Malignancies
  Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy : Involved-field versus involved-node radiotherapy (pages 4156–4165)
  Belinda A. Campbell, Joseph M. Connors, Randy D. Gascoyne, W. James Morris, Tom Pickles and Laurie H. Sehn
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.26687
  
  This is the first known body of work to apply the concept of involved-node radiotherapy to limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. Reducing the field size beyond the conventional involved-field radiotherapy field appears to be safe, with a very low risk of marginal recurrence and no impact on progression-free or overall survival rates.
  - Abstract
  - Full Article (HTML)
  - PDF(238K)
  - References
  - Request Permissions
9. Discipline
  
  Hematologic Malignancies
  Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era (pages 4166–4172)
  Hiroyuki Takahashi, Naoto Tomita, Masahiro Yokoyama, Saburo Tsunoda, Takahiro Yano, Kayoko Murayama, Chizuko Hashimoto, Kazuo Tamura, Kazuya Sato and Yoshiaki Ishigatsubo
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.27381
  
  Retrospective analysis of 1221 diffuse large B-cell lymphoma patients who have been uniformly treated with R-CHOP therapy detects prognostic impact for 8 extranodal sites. Waldeyer ring involvement has significantly better prognosis and should be treated as an extranodal lesion.
  - Abstract
  - Full Article (HTML)
  - PDF(271K)
  - References
  - Request Permissions
10. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (pages 4173–4183)
  Nalan Akyurek, Aysegul Uner, Mustafa Benekli and Ibrahim Barista
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.27396
  
  Diffuse large B-cell lymphomas with rearrangements of MYC or BCL6 are significantly associated with worse overall survival in patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Patients with concurrent rearrangements of MYC and BCL2 and/or BCL6 have extremely poor prognosis. The results suggest that analysis of MYC gene rearrangement along with BCL2 and BCL6is critical in identification of high-risk patients with poor prognosis.
  - Abstract
  - Full Article (HTML)
  - PDF(467K)
  - References
  - Request Permissions
11. Disease Site
  
  Melanoma
  Single versus multiple primary melanomas : Old questions and new answers(pages 4184–4192)
  Charlotte Hwa, Leah S. Price, Ilana Belitskaya-Levy, Michelle W. Ma, Richard L. Shapiro, Russell S. Berman, Hideko Kamino, Farbod Darvishian, Iman Osman and Jennifer A. Stein
  
  Article first published online: 13 JAN 2012 | DOI: 10.1002/cncr.27407
  
  There is no difference in the presence or absence of mitosis, a marker of tumor proliferation, in tumors from patients with single and multiple primary melanomas. Because it has been demonstrated that the presence of mitosis is a powerful prognostic marker in patients with melanoma, the current findings suggest that the tumors behave similarly in patients with single and multiple primary melanomas.
  - Abstract
  - Full Article (HTML)
  - PDF(198K)
  - References
  - Request Permissions
12. Neuro-Oncology
  Extended field stereotactic radiosurgery for recurrent glioblastoma (pages 4193–4200)
  Tomoyuki Koga, Keisuke Maruyama, Minoru Tanaka, Yasushi Ino, Nobuhito Saito, Keiichi Nakagawa, Junji Shibahara and Tomoki Todo
  
  Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.27372
  
  To exploit the usefulness of stereotactic radiosurgery (SRS) for small recurrent lesions of glioblastoma, the modified clinical target volume is defined by adding a 0.5- to 1-cm margin to the gadolinium-enhanced area (extended field SRS), in contrast to conventional SRS using no margin to set the clinical target volume. Extended field SRS is superior to conventional SRS in the local control of small recurrent lesions of glioblastoma, although a further device to suppress remote dissemination may be necessary to increase survival.
  - Abstract
  - Full Article (HTML)
  - PDF(444K)
  - References
  - Request Permissions
13. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients (pages 4201–4211)
  Véronique Quillien, Audrey Lavenu, Lucie Karayan-Tapon, Catherine Carpentier, Marianne Labussière, Thierry Lesimple, Olivier Chinot, Michel Wager, Jérome Honnorat, Stephan Saikali, Frédéric Fina, Marc Sanson and Dominique Figarella-Branger
  
  Article first published online: 31 JAN 2012 | DOI: 10.1002/cncr.27392
  
  In this study, O⁶-methylguanine-DNA-methyltranferase status analyzed by either methylation-specific polymerase chain reaction, methylation-sensitive high-resolution melting, pyrosequencing, MethyLight, or immunohistochemistry is associated with overall survival and progression-free survival, but depending on the method, the percentage of patients classified as potential responders to alkylating agents varies from 33% to 60%. Among the tested techniques, we can recommend pyrosequencing because of its clinical performance and its good reproducibility and sensitivity.
  - Abstract
  - Full Article (HTML)
  - PDF(723K)
  - References
  - Request Permissions
14. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis (pages 4212–4219)
  Daniela L. Buscariollo, Henry S. Park, Kenneth B. Roberts and James B. Yu
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.27373
  
  There is a robust association between primary or adjuvant radiotherapy (RT) and improved median overall survival in patients with atypical teratoid rhabdoid tumor (ATRT), and that association is stronger for patients aged ≤3 years. The inclusion of initial RT for patients aged ≤3 years in future prospective studies is needed to delineate the role of RT in the treatment of ATRT.
  - Abstract
  - Full Article (HTML)
  - PDF(239K)
  - References
  - Request Permissions
15. Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004-2007 (pages 4220–4227)
  Linh M. Duong, Bridget J. McCarthy, Roger E. McLendon, Therese A. Dolecek, Carol Kruchko, Lynda L. Douglas and Umed A. Ajani
  
  Article first published online: 3 JAN 2012 | DOI: 10.1002/cncr.27390
  
  This large population-based study adds new insights into the descriptive epidemiology of primary spinal cord, spinal meninges, and cauda equina tumors. It provides in-depth analyses of the incidence of these tumors on a national level.
  - Abstract
  - Full Article (HTML)
  - PDF(209K)
  - References
  - Request Permissions
16. Improving prognosis of glioblastoma in the 21st century: Who has benefited most?(pages 4228–4234)
  Yaacov Richard Lawrence, Mark V. Mishra, Maria Werner-Wasik, David W. Andrews, Timothy N. Showalter, Jon Glass, Xinglei Shen, Zvi Symon and Adam P. Dicker
  
  Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26685
  
  Overall survival in glioblastoma improved incrementally from 2001 to 2007. However, this improvement has been confined to patients less than 70 years of age and has been most prominent among patients living in high-income districts.
  - Abstract
  - Full Article (HTML)
  - PDF(287K)
  - References
  - Request Permissions
17. Soft Tissue and Bone Sarcoma
  Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas (pages 4235–4243)
  Keith M. Skubitz, Princy Francis, Amy P. N. Skubitz, Xianghua Luo and Mef Nilbert
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.26733
  
  Hierarchical clustering using a composite gene set derived from studies of renal carcinoma, ovarian carcinoma, and aggressive fibromatosis suggest the existence of subsets of 73 samples of high-grade soft tissue sarcoma (STS). Analysis reveals differences in the time to development of metastatic disease between the clusters defined by the first branch point of the clustering dendrogram, and also among the 4 different clusters defined by the second branch points, suggesting that such an approach may be useful in the management of STS.
  - Abstract
  - Full Article (HTML)
  - PDF(789K)
  - References
  - Request Permissions
18. Discipline
  
  Clinical Trials
  Phase 2 results from Radiation Therapy Oncology Group Study 0537 : A phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia (pages 4244–4252)
  Raimond K. W. Wong, Jennifer L. James, Stephen Sagar, Gwen Wyatt, Phuc Felix Nguyen-Tân, Anurag K. Singh, Barbara Lukaszczyk, Francis Cardinale, Alexander M. Yeh and Lawrence Berk
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.27382
  
  Acupuncture-like transcutaneous nerve stimulation (ALTENS) treatment for radiation-induced xerostomia can be delivered uniformly in a cooperative, multicenter setting and has possible beneficial treatment response. Given these positive results, the phase 3 component of this study comparing ALTENS with pilocarpine was initiated.
  - Abstract
  - Full Article (HTML)
  - PDF(293K)
  - References
  - Request Permissions
19. A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks (pages 4253–4261)
  Kristin L. Reiter, Paula H. Song, Lori Minasian, Marjorie Good, Bryan J. Weiner and Ann Scheck McAlearney
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.27375
  
  The literature currently provides little practical guidance to assist provider organizations in analyzing the return on investment, or business case, for establishing and operating provider-based research networks, such as the National Cancer Institute's Community Clinical Oncology Program (CCOP). In this report, the authors present a conceptual model of the business case, a spreadsheet-based tool and advice to help evaluate the business case for provider participation in a CCOP organization.
  - Abstract
  - Full Article (HTML)
  - PDF(157K)
  - References
  - Request Permissions
20. A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors (pages 4262–4270)
  Caio M. Rocha-Lima, Soley Bayraktar, Jessica MacIntyre, Luis Raez, Aurea M. Flores, Annapoorna Ferrell, Eric H. Rubin, Elizabeth A. Poplin, Antoinette R. Tan, Antonio Lucarelli and Naseem Zojwalla
  
  Article first published online: 31 JAN 2012 | DOI: 10.1002/cncr.27428
  
  This study shows that E7974 once every 21-day cycle shows antitumor activity in patients with refractory solid tumors. The recommended phase 2 dose is 0.45 mg/m².
  - Abstract
  - Full Article (HTML)
  - PDF(409K)
  - References
  - Request Permissions
21. Disparities Research
  Survival disparities by Medicaid status : An analysis of 8 cancers (pages 4271–4279)
  Siran M. Koroukian, Paul M. Bakaki and Derek Raghavan
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.27380
  
  This study documents important disparities in survival outcomes for 8 cancers by Medicaid status. These disparities persist after adjusting for patient demographics, marital status, and county of residence.
  - Abstract
  - Full Article (HTML)
  - PDF(334K)
  - References
  - Request Permissions
22. Explaining racial differences in prostate cancer mortality (pages 4280–4289)
  Glen B. Taksler, Nancy L. Keating and David M. Cutler
  
  Article first published online: 13 JAN 2012 | DOI: 10.1002/cncr.27379
  
  Higher incidence of prostate cancer accounted for 76% of racial differences in prostate cancer mortality between blacks and whites, with the remainder due to higher stage-specific mortality after diagnosis. More frequent prostate-specific antigen testing for black and low-income males could potentially reduce the prostate cancer mortality gap through earlier diagnosis of tumors that otherwise may become metastatic.
  - Abstract
  - Full Article (HTML)
  - PDF(272K)
  - References
  - Request Permissions
23. Epidemiology
  Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003 (pages 4290–4297)
  Ramandeep S. Arora, Robert D. Alston, Tim O. B. Eden, Marco Geraci and Jillian M Birch
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.27403
  
  Malignant germ cell tumors, which display heterogeneity by histology and site, occur at all ages with incidence peaks in infancy and young adulthood. Regardless of site, the similarity in shapes of the age-incidence curves of patients with germ cell tumors suggests a common initiation of these tumors in embryonic/fetal life with variable rates of tumor progression as a result of local factors or events during the postnatal and pubertal periods.
  - Abstract
  - Full Article (HTML)
  - PDF(750K)
  - References
  - Request Permissions
24. Medical Oncology
  Aberrant DNA methylation of tumor-related genes in oral rinse : A noninvasive method for detection of oral squamous cell carcinoma (pages 4298–4308)
  Satoshi Nagata, Tomofumi Hamada, Norishige Yamada, Seiya Yokoyama, Sho Kitamoto, Yuji Kanmura, Masahiro Nomura, Yoshiaki Kamikawa, Suguru Yonezawa and Kazumasa Sugihara
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.27417
  
  Aberrant methylation of a combination of marker genes present in oral rinse samples can be used to detect oral squamous cell carcinoma (OSCC) with over 90% sensitivity and specificity. Analysis of the methylation status of marker genes from oral rinse samples reveals great potential for the noninvasive detection of OSCC.
  - Abstract
  - Full Article (HTML)
  - PDF(528K)
  - References
  - Request Permissions
25. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer : A population-based analysis (pages 4309–4320)
  Hanna K. Sanoff, William R. Carpenter, Janet Freburger, Ling Li, Kun Chen, Leah L. Zullig, Richard M. Goldberg, Maria J. Schymura and Deborah Schrag
  
  Article first published online: 31 JAN 2012 | DOI: 10.1002/cncr.27422
  
  The addition of oxaliplatin to 5-fluorouracil-containing adjuvant therapy for stage III colon cancer increases the rate of outpatient adverse events reported in Medicare/Medicaid billing claims. Oxaliplatin does not increase emergency room use, hospitalization, or early mortality.
  - Abstract
  - Full Article (HTML)
  - PDF(681K)
  - References
  - Request Permissions
26. Pediatric Oncology
  Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients (pages 4321–4330)
  Anthony M. Christensen, Jennifer L. Pauley, Alejandro R. Molinelli, John C. Panetta, Deborah A. Ward, Clinton F. Stewart, James M. Hoffman, Scott C. Howard, Ching-Hon Pui, Alberto S. Pappo, Mary V. Relling and Kristine R. Crews
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.27378
  
  Glucarpidase is an infrequently used but effective intervention for high-dose methotrexate-induced acute kidney injury. Resumption of high-dose methotrexate after glucarpidase administration is feasible.
  - Abstract
  - Full Article (HTML)
  - PDF(421K)
  - References
  - Request Permissions
27. Symptom Control and Palliative Care
  Augmenting advance care planning in poor prognosis cancer with a video decision aid : A preintervention-postintervention study (pages 4331–4338)
  Angelo E. Volandes, Tomer T. Levin, Susan Slovin, Richard D. Carvajal, Eileen M. O'Reilly, Mary Louise Keohan, Maria Theodoulou, Maura Dickler, John F. Gerecitano, Michael Morris, Andrew S. Epstein, Anastazia Naka-Blackstone, Elizabeth S. Walker-Corkery, Yuchiao Chang and Ariela Noy
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.27423
  
  Patients with advanced cancer who use a video decision aid are more knowledgeable about their end-of-life decisions and often prefer not to have cardiopulmonary resuscitation (CPR) or ventilation attempted. Despite having preferences against the use of CPR and ventilation, patients are unlikely to have a code status consistent with their preferences.
  - Abstract
  - Full Article (HTML)
  - PDF(340K)
  - References
  - Request Permissions
28. Radiation therapy at the end of life in patients with incurable nonsmall cell lung cancer (pages 4339–4345)
  Nirav S. Kapadia, Rizvan Mamet, Carrie Zornosa, Joyce C. Niland, Thomas A. D'Amico and James A. Hayman
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.27401
  
  The authors characterize the use of radiotherapy in patients with incurable nonsmall cell lung cancer during their last 14 days of life and observe that its use is infrequent, it is delivered more commonly to younger patients with more advanced disease, and it is completed as planned only approximately half of the time. There is also significant institutional variation in its use; thus, future investigations should aim to expand this research to other cancers and settings and to investigate the clinical benefit of such treatment.
  - Abstract
  - Full Article (HTML)
  - PDF(224K)
  - References
  - Request Permissions
29. Translational Research
  Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation (pages 4346–4353)
  Jennifer Y. Pan, Jaffer A. Ajani, Jian Gu, Yubo Gong, Angel Quin, Maosheng Hung, Xifeng Wu and Julie G. Izzo
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.26581
  
  Aurora kinase functional polymorphisms impacts clinical outcome of esophageal cancer treated with preoperative chemoradiation.
  - Abstract
  - Full Article (HTML)
  - PDF(156K)
  - References
  - Request Permissions
30. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ (pages 4354–4362)
  Anupama Sharma, Ursula Koldovsky, Shuwen Xu, Rosemarie Mick, Robert Roses, Elizabeth Fitzpatrick, Susan Weinstein, Harvey Nisenbaum, Bruce L. Levine, Kevin Fox, Paul Zhang, Gary Koski and Brian J. Czerniecki
  
  Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.26734
  
  Vaccination against HER-2/neu induces decline and/or eradication of HER-2/neuexpression. These findings warrant further exploration of HER-2/neu vaccination in estrogen-independent breast cancer but highlight the need to target additional tumor-associated antigens and pathways.
  - Abstract
  - Full Article (HTML)
  - PDF(581K)
  - References
  - Request Permissions
Correspondence
1. Differences in vitamin D status likely explain racial disparities in breast cancer mortality rates in the southeast (page 4363)
  William B. Grant, Luca Mascitelli and Mark R. Goldstein
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.27374
  - Abstract
  - Full Article (HTML)
  - PDF(58K)
  - Request Permissions
2. Reply to differences in vitamin D status likely explain racial disparities in breast cancer mortality rates in the southeast (page 4364)
  Swann Arp Adams, Susan E. Steck and James R. Hébert
  
  Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.27383
  - Abstract
  - Full Article (HTML)
  - PDF(65K)
  - Request Permissions
Erratum
1. You have free access to this content
  Erratum (page 4365)
  Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.27384
  
  This article corrects:
  
  A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
  
  Vol. 118, Issue 12, 3128–3134, Article first published online: 17 OCT 2011
  - Abstract
  - Full Article (HTML)
  - PDF(39K)
  - Request Permissions

过刊浏览

发表评论网友评论(13)

期刊中心

Cancer
(CANCER-AM CANCER SOC) 《癌症》

全球精选文摘

全球精选全文

中国作者重要发表

最新一期

CancerScope

Original Articles

Disease Site

Breast Disease

Discipline

Gastrointestinal Disease

Disease Site

Genitourinary Disease

Hematologic Malignancies

Discipline

Hematologic Malignancies

Disease Site

Melanoma

Neuro-Oncology

Soft Tissue and Bone Sarcoma

Discipline

Clinical Trials

Disparities Research

Epidemiology

Medical Oncology

Pediatric Oncology

Symptom Control and Palliative Care

Translational Research

Correspondence

Erratum

过刊浏览

同类期刊影响因子排行

期刊中心

Cancer (CANCER-AM CANCER SOC) 《癌症》

全球精选文摘

全球精选全文

中国作者重要发表

最新一期

CancerScope

Original Articles

Disease Site

Breast Disease

Discipline

Gastrointestinal Disease

Disease Site

Genitourinary Disease

Hematologic Malignancies

Discipline

Hematologic Malignancies

Disease Site

Melanoma

Neuro-Oncology

Soft Tissue and Bone Sarcoma

Discipline

Clinical Trials

Disparities Research

Epidemiology

Medical Oncology

Pediatric Oncology

Symptom Control and Palliative Care

Translational Research

Correspondence

Erratum

过刊浏览

同类期刊影响因子排行

Cancer
(CANCER-AM CANCER SOC) 《癌症》